1 active not recruiting, 1 completed, 1 terminated, 1 withdrawn. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow 177Lu-PNT2002: new trials by email Literature Review of 177Lu-PNT2002 trials Research Report on 177Lu-PNT2002
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PSMA Therapy and Immunotherapy in Kidney Cancer Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL - Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-10-01 | 2025-08-19 | |
| 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma 177Lu-PNT2002 - Adenoid Cystic Carcinoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2025-02-10 | 2026-01-22 |
| 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 93 | 2022-09-02 | 2026-05-26 |
| Radioligand fOr locAl raDiorecurrent proStaTe cancER 177Lu-PNT2002, High Dose Radiation - Prostate Cancer | Phase 1 / Phase 2 | Completed | Glenn Bauman | 3 | 2022-03-17 | 2025-09-12 |
Prostatic Neoplasms (2) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Kidney Neoplasms (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Glenn Bauman (1) · Jonsson Comprehensive Cancer Center (1)
United States (2) · Canada (1)
Amar Kishan, MD (1) · Ana Kiess, MD, PhD (1) · Glenn Bauman, MD (1) · Yasser Ged, MD (1)